0001567619-22-005512.txt : 20220224 0001567619-22-005512.hdr.sgml : 20220224 20220224180559 ACCESSION NUMBER: 0001567619-22-005512 CONFORMED SUBMISSION TYPE: 4 PUBLIC DOCUMENT COUNT: 1 CONFORMED PERIOD OF REPORT: 20220222 FILED AS OF DATE: 20220224 DATE AS OF CHANGE: 20220224 REPORTING-OWNER: OWNER DATA: COMPANY CONFORMED NAME: Eichorn Laura G. CENTRAL INDEX KEY: 0001861067 FILING VALUES: FORM TYPE: 4 SEC ACT: 1934 Act SEC FILE NUMBER: 001-40604 FILM NUMBER: 22673380 MAIL ADDRESS: STREET 1: IMAGO BIOSCIENCES, INC. STREET 2: 329 OYSTER POINT BLVD. 3RD FL CITY: SOUTH SAN FRANCISCO STATE: CA ZIP: 94080 ISSUER: COMPANY DATA: COMPANY CONFORMED NAME: Imago BioSciences, Inc. CENTRAL INDEX KEY: 0001623715 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] IRS NUMBER: 454915810 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 BUSINESS ADDRESS: STREET 1: 329 OYSTER POINT BLVD., 3RD FLOOR CITY: SOUTH SAN FRANCISCO STATE: CA ZIP: 94080 BUSINESS PHONE: 650 325 5156 MAIL ADDRESS: STREET 1: 329 OYSTER POINT BLVD., 3RD FLOOR CITY: SOUTH SAN FRANCISCO STATE: CA ZIP: 94080 4 1 doc1.xml FORM 4 X0306 4 2022-02-22 0 0001623715 Imago BioSciences, Inc. IMGO 0001861067 Eichorn Laura G. C/O IMAGO BIOSCIENCES, INC. 329 OYSTER POINT BLVD, 3RD FLOOR SOUTH SAN FRANCISCO CA 94080 0 1 0 0 See Remarks Common Stock 2022-02-22 4 M 0 8000 2.52 A 215737 D Common Stock 2022-02-22 4 S 0 7600 21.5722 D 208137 D Common Stock 2022-02-22 4 S 0 400 22.16 D 207737 D Stock Option (Right to Buy) 2.52 2022-02-22 4 M 0 8000 0.00 D 2021-01-01 2027-03-28 Common Stock 8000 101956 D Transaction made pursuant to a 10b5-1 trading plan adopted by the Reporting Person. The transaction was executed in multiple trades in prices ranging from $21.03 to $21.97, inclusive. The price reported in Column 4 above reflects the weighted average sale price. The reporting person hereby undertakes to provide to the Securities and Exchange Commission staff, the Issuer, or a security holder of the Issuer, upon request, full information regarding the number of shares sold at each respective price within the range set forth in this footnote. The transaction was executed in multiple trades in prices ranging from $22.07 to $22.21, inclusive. The price reported in Column 4 above reflects the weighted average sale price. The reporting person hereby undertakes to provide to the Securities and Exchange Commission staff, the Issuer, or a security holder of the Issuer, upon request, full information regarding the number of shares sold at each respective price within the range set forth in this footnote. Chief Operating Officer/Interim CFO /s/ Hugh Rienhoff, as Attorney-in-fact for Laura Eichorn 2022-02-24